Frequent abnormalities of the immune system in gliomas and correlation with the WHO grading system of malignancy

Journal of Neuroimmunology

Volumn 226, Issue 1-2, 2010, Pages 136-142

  Gousias, K ^a,b   Markou, M ^c   Arzoglou, V ^d   Voulgaris, S ^a   Vartholomatos, G ^a   Kostoula, A ^a   Voulgari, P ^a   Polyzoidis, K ^d   Kyritsis, A P ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c Godeshoehe Clinic   (Germany)

^d University Hospital of Thessaloniki   (Greece)

Author keywords

CD4+ counts; Gliomas; Impairment of immunity; Ratio CD4 CD8; WHO grading system

Indexed keywords

ANTINUCLEAR ANTIBODY; CARDIOLIPIN ANTIBODY; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CELL NUCLEUS ANTIGEN; COMPLEMENT COMPONENT C4; DOUBLE STRANDED DNA ANTIBODY; GRANZYME B; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 16; INTERLEUKIN 2; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; LEUKOCYTE ANTIGEN;

ADULT; ARTICLE; CANCER GRADING; CASE CONTROL STUDY; CD3+ T LYMPHOCYTE; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GLIOMA; HUMAN; HUMORAL IMMUNITY; IMMUNOPATHOLOGY; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; NATURAL KILLER CELL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; VIRUS; WORLD HEALTH ORGANIZATION; AGED; BLOOD; CLASSIFICATION; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNE SYSTEM DISEASES; IMMUNOLOGY; METABOLISM; MIDDLE AGED; NERVOUS SYSTEM NEOPLASMS; NONPARAMETRIC TEST; PROCEDURES; RETROSPECTIVE STUDY; STATISTICAL MODEL;

ADULT; AGED; ANTIGENS, CD; CASE-CONTROL STUDIES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GLIOMA; HUMANS; IMMUNE SYSTEM DISEASES; LOGISTIC MODELS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NERVOUS SYSTEM NEOPLASMS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; WORLD HEALTH ORGANIZATION;

EID: 77956345180     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.05.027     Document Type: Article

References (41)

1. Ausiello C.M., Palma C., Maleci A., et al. Cell mediated cytotoxity and cytokine production in peripheral blood mononuclear cells of glioma patients. Eur. J. Cancer 1991, 27:646-650.
2. Barcia C., Gomez A., Gallego-Sanchez J.M. Infiltrating CTLs in human glioblastoma establish immunological synapses with tumorigenic cells. Am. J. Pathol. 2009, 175(2):786-798.
3. Bazan J.F., Schall T.J. Interleukin-16 or not?. Nature 1996, 381:29-30.
4. Bhaskara V.K., Challa S., Panigrahi, et al. Differential PARP cleavage: an indication for existence of multiple forms of cell death in human gliomas. Neurol. India 2009, 57(3):264-268.
5. Bhondeley M.K., Mehra R.D., Mehra N.K., et al. Imbalances in T cell subpopulations in human gliomas. J. Neurosurg. 1988, 68(4):589-593.
6. Cobbs C.S., Harkins L., Samanta M., et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 2002, 62:3347-3350.
7. Cobbs C.S., Soroceanu L., Denham S., et al. Modulation of oncogenic phenotype in human glioma cells by cytomegalovirus IE1-mediated mitogenicity. Cancer Res. 2008, 68(3):724-730.
8. Dix A.R., Brooks W.H., Roszman T.L., et al. Immune defects observed in patients with primary malignant brain tumors. J. Immunol. 1999, 100:216-232.
9. Edge M.D., Rimland D. Community-acquired bacteriaemia in HIV positive patients: protective benefit of co-trimoxazole. AIDS 1996, 10(14):1635-1639.
10. Elliott L.H., Brooks W.H., Roszman T.L. Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors. J. Immunol. 1984, 132:1208-1215.
11. Fecci P.E., Mitchell D.A., Whitesides J.F., et al. Increased regulatory t-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006, 66(6):3294-3302.
12. Friese M.A., Steinle A., Weller M. The innate immune response in the central nervous system and its role in glioma immune surveillance. Onkologie 2004, 27:487-491.
13. Froelich C.J., Dixit V.M., Yang X., et al. Lymphocyte granule-mediated apoptosis: matters of viral mimicry and deadly proteases. Immunol. Today 1998, 19:30-36.
14. Gasque P., Julen N., Ischenko A., et al. Expression of complement components of the alternative pathway by glioma cell lines. J. Immunol. 1992, 149:381-1387.
15. Gasque P., Ischenko A., Legoedec J., et al. Expression of the complement classical pathway by human glioma in culture. J. Biol. Chem. 1993, 268:25068-25074.
16. Hekim N., Sayin E., Demirkaya E., et al. Serum IgM level as an index of malignancy in brain tumours. Acta Neurochir. 1981, 59:227-230.
17. Huettner C., Czub S., Kerkau S., et al. Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vivo. Anticancer Res. 1997, 17:3217-3224.
18. Kempuraj D., Devi R.S., Madhappan B., et al. T lymphocyte subsets and immunoglobulins in intracranial tumor patients before and after treatment, and based on histological type of tumors. Int. J. Immunopathol. Pharmacol. 2004, 17(1):57-64.
19. Lau S., Chen Y.Y., Chen W.G., et al. Lack of association of cytomegalovirus with human brain tumors. Mod. Pathol. 2005, 18:838-843.
20. Learn C.A., Fecci P.E., Schmittling R.J., et al. Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers. Clin. Cancer Res. 2006, 12(24):7306-7315.
21. Liebrich M., Guo L.H., Schluesener H.J., et al. Expression of Interleukin 16 by tumor-associated macrophages/activated microglia in high-grade astrocytic brain tumors. Arch. Immunol. Ther. Exp. 2007, 55:41-47.
22. Manjula S., Aroor A.R., Raja A., et al. Serum immunoglobulins in brain tumours. Acta Neurochir. (Wien) 1992, 115:103-105.
23. McIlroy D., Cartron P.F., Tuffery P., et al. A triple-mutated allele of granzyme B incapable of inducing apoptosis. PNAS 2003, 100:2562-2567.
24. Mitchell D., Fecci P., Sampson J., et al. Immunotherapy of malignant brain tumors. Immunol. Rev. 2008, 222:70-100.
25. Mitchell D., Xie W., Schmittling R., et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-Oncol. 2008, 10:10-18.
26. Mahaley M.S., Brooks W.H., Roszman T.L., et al. Imunobiology of primary intracranial tumors. Part I. Studies of the cellular and humoral general immune competence of brain-tumor patients. J. Neurosurg. 1977, 46:467-476.
27. Nakao S., Terano M., Yamashita J., et al. Serum immunoglobulin (IgG, IgM, IgA) levels in patients with primary brain tumors. No To Shinkei 1977, 29(9):1005-1009.
28. Palma L., Di Lorenzo N., Guidetti B. Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas, incidence, fate and relevance to prognosis in 228 operated cases. J. Neurosurg. 1978, 49:854-861.
29. Peracoli M.S.T., Montelli T.C.B., Scares A.M.V.C., et al. Immunological alterations in patients with primary tumors in central nervous system. Arq. Neuropsiquiatr. 1999, 57:539-546.
30. Rapp M., Oscan Z., Steiger H.J., et al. Cellular immunity of patients with malignant glioma: prerequisites for dendritic cell vaccination immunotherapy. J. Neurosurg. 2006, 105(1):41-50.
31. Reuter J.D., Gomez D.L., Wilson J.H., et al. Systemic immune deficiency necessary for cytomegalovirus invasion of the mature brain. J. Virol. 2004, 78(3):1473-1487.
32. Roussel E., Gingras M.C., Grimm E.A., et al. Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas. Clin. Exp. Immunol. 1996, 105:344-352.
33. Tada M., de Tribolet N. Immunobiology of malignant gliomas. J. Clin. Neurosci. 1996, 3(2):102-113.
34. Twomey J.J., Rossen R.D., Lewis V.M., et al. Rheumatoid factor and tumor-host interaction. Proc. Natl. Acad. Sci. USA 1976, 73(6):2106-2108.
35. van den Pol A.N., Reuter J.D., Santarelli J.G. Enhanced cytomegalovirus infection of developing brain independent of the adaptive immune system. J. Virol. 2002, 76(17):8842-8854.
36. Weiss J.F., Morantz R.A., Bradley W.P., et al. Serum acute-phase proteins and immunoglobulins in patients with gliomas. Cancer Res. 1979, 39:542-544.
37. Wrensch M., Weinberg A., Wiencke J., et al. Prevalence of antibodies to four herpesviruses among adults with glioma and controls. Am. J. Epidemiol. 2001, 154:161-165.
38. Wrensch M., Weinberg A., Wiencke J., et al. History of chickenbox and shingles and precalence of antibodies to varicella-zoster virus and three other herpes viruses among adults with glioma and controls. Am. J. Epidemiol. 2005, 161:929-938.
39. Yüceer N., Arasil E., Temiz C. Serum immunoglobulins in brain tumours and lumbar disc diseases. NeuroReport 2000, 11(2):279-281.
40. Zisakis A., Piperi C., Themistocleous M., et al. Comparative analysis of peripheral and localised cytokine secretion in glioblastoma patients. Cytokine 2007, 39:99-105.
41. Zou J.P., Morford L.A., Chougnet C., et al. Human glioma-induced immunosuppression involves soluble factors that alters monocyte cytokine profile and surface markers. J. Immunol. 1999, 162:4882-4892.